
    
      OUTLINE:

      This is a dose-escalation study of alpha-TEA.

      Patients receive one of 4 doses of alpha-TEA orally (PO) on days 1-14. Patients also receive
      trastuzumab on day 1 of cycle 1 and then every 3 weeks per standard of care. Cycles repeat
      every 28 days in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up every 6 months for 4 years.
    
  